|Market Research A to Z | Company Profiles A to Z | Register | Contact Us | Shopping Basket|
|+44 (0) 203 086 8600 Call us on|
The leukaemia therapeutics market has been forecast to rise at a compound annual growth rate (CAGR) of 9.5% between 2011 and 2018, increasing from a valuation of $4 billion, to be worth a market value of $7.6 billion by 2018.
Leukaemia is a type of cancer of the blood or bone marrow characterised by an abnormal increase of immature white blood cells called "blasts".
The four indications covered by the leukaemia therapeutics market are the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML).
In general, there are two types of leukemia research: clinical or translational research and basic research. Clinical/translational research focuses on studying the disease in a defined and generally immediately patient-applicable way, such as testing a new drug in patients. By contrast, basic science research studies the disease process at a distance, such as seeing whether a suspected carcinogen can cause leukemic changes in isolated cells in the laboratory or how the DNA changes inside leukemia cells as the disease progresses.
Lat year the leukaemia therapeutics market was dominated by branded drugs such as Gleevec (imatinib), Tasigna, Clolar and Arranon with a market share of 85%, while generics such as vincristine, doxorubicin, methotrexate and cytarabine accounted for the remaining 15% share.
The US was the leading region within the leukaemia therapeutics market with an estimated sales value of $1.8 billion in 2011 and an approximate share of 44.3%. The US market is expected to grow at a CAGR of 10% between 2011 and 2018 to record a sales value of $3.5 billion.
For more information on the leukaemia therapeutics market, see the latest research: Leukaemia Therapeutics Market
Follow us on Twitter @CandMResearch
Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support
For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.
Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.
We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.